<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667989</url>
  </required_header>
  <id_info>
    <org_study_id>MIBGinCRT</org_study_id>
    <nct_id>NCT03667989</nct_id>
  </id_info>
  <brief_title>SPECT-based Prediction and Evaluation of CRT Efficacy in CHF</brief_title>
  <acronym>MIBGinCRT</acronym>
  <official_title>Single-photon Emission Computed Tomography for Prediction and Evaluation of Cardiac Resynchronization Therapy Efficacy in Chronic Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the state of the cardiac sympathetic activity and the severity of
      ventricular dyssynchrony in chronic heart failure patients and assesses the capabilities of
      radionuclide indication methods in determining the prognosis and evaluating the results of
      cardiac resynchronization therapy in chronic heart failure patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In heart failure, abnormal activation of cardiac sympathetic system has been shown to be of
      pathophysiological significance. However, the left ventricular (LV) dyssynchrony has a
      detrimental effect on LV systolic and diastolic functions in heart failure patients. The
      effects of LV dyssynchrony on cardiac sympathetic activity are not yet fully understood.
      Dilated cardiomyopathy is a common cause of severe chronic heart failure. Cardiac
      resynchronization therapy (CRT) is a disease modifying device-driven treatment that can
      reduce morbidity and mortality in patients with heart failure. However, this type of
      treatment does not lead to the expected results in 25% to 30% of patients despite the
      successful implantation of a CRT device. In addition, CRT is associated with high cost and
      potential morbidity. Therefore, the search for new highly informative criteria for selecting
      patients for this type of treatment remains a relevant task of modern medicine. It is
      expected that the results obtained will complement and expand current state of knowledge
      regarding the relationships between cardiac remodeling processes and the state of cardiac
      sympathetic activity. In addition, obtained data will allow to predict LV remodeling dynamics
      after the correction of contractile dysfunction of the heart.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CRT response</measure>
    <time_frame>One year</time_frame>
    <description>ESV decreasing equal or more than 15%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>123I-MIBG CZT SPECT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Assessment of cardiac sympathetic innervation by 123I-MIBG</intervention_name>
    <description>Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT</description>
    <arm_group_label>123I-MIBG CZT SPECT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic heart failure NYHA III and IV class

          -  LVEF ≤ 35 %

          -  QRS ≥ 150 ms on ECG

          -  The presence of LBBB on ECG

          -  Sinus rhythm

          -  Optimal pharmacological treatment of heart failure

        Exclusion Criteria:

          -  Contraindications to SPECT due to hypersensitivity to radiopharmacuticals such as
             2-methoxy-isobutyl-isonitrile-(99mTc) and (123)I-Meta-iodobenzylguanidine or any of
             the excipients

          -  Pregnancy

          -  Breastfeeding

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey V Popov, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tomsk NRMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna I Mishkina, MD</last_name>
    <phone>+79095420999</phone>
    <email>anna123.2013@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Konstantin V Zavadovsky, MD, PhD</last_name>
    <phone>+79039518791</phone>
    <email>Konstz@cardio-tomsk.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Research Institute, Tomsk NRMC</name>
      <address>
        <city>Tomsk</city>
        <state>Tomsk Region</state>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Anfinogenova, MD, PhD</last_name>
      <phone>+73822554111</phone>
      <email>anfiyj@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPECT</keyword>
  <keyword>123I-MIBG</keyword>
  <keyword>Chronic heart failure</keyword>
  <keyword>Cardiac resynchronization therapy</keyword>
  <keyword>CZT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

